Association Between Cerebral Microbleeds and Circulating Levels of Mid-Regional Pro-Adrenomedullin.
J Alzheimers Dis
; 88(2): 731-741, 2022.
Article
em En
| MEDLINE
| ID: mdl-35694922
ABSTRACT
BACKGROUND:
Mid-regional pro-adrenomedullin (MR-proADM) is a novel biomarker for cognitive decline based on its association with cerebral small vessel disease (SVD). Cerebral microbleeds (MBs) are characteristic of SVD; however, a direct association between MR-proADM and MBs has not been explored.OBJECTIVE:
We aimed to examine whether circulating levels of MR-proADM are associated with the identification of MBs by brain magnetic resonance imaging (MRI) and whether this association could be linked with cognitive impairment.METHODS:
In total, 214 participants (mean age 75.9 years) without history of cerebral infarction or dementia were prospectively enrolled. All participants underwent brain MRI, higher cognitive function testing, blood biochemistry evaluation, lifestyle examination, and blood MR-proADM measurement using a time-resolved amplified cryptate emission technology assay. For between-group comparisons, the participants were divided into two groups according to whether their levels of MR-proADM were normal (<â0.65ânmol/L) or high (≥0.65ânmol/L).RESULTS:
The mean MR-proADM level was 0.515±0.127ânmol/L. There were significant between-group differences in age, hypertension, and HbA1c levels (pâ<â0.05). In the high MR-proADM group, the MR-proADM level was associated with the identification of MBs on brain MR images and indications of mild cognitive impairment (MCI). In participants with ≥3 MBs and MCI, high MR-proADM levels remained a risk factor after multivariate adjustment (OR 2.94; pâ<â0.05).CONCLUSION:
High levels of MR-proADM may be a surrogate marker for the early detection of cognitive decline associated with the formation of cerebral MBs. This marker would be valuable during routine clinical examinations of geriatric patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Precursores de Proteínas
/
Adrenomedulina
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Limite:
Aged
/
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article